Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.52 |
| ▸ | FABP4 | P15090 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315898 | 1.00 | HTR6 (0.52) | HTR6FABP4HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL6047574 | 0.99 | HTR6 (0.51) | HTR6FABP4HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL6047575 | 0.99 | HTR6 (0.51) | HTR6FABP4HTR1ADRD2HTR2A | |
| SCHEMBL4310052 | 0.88 | HTR6 (0.57) | HTR6FABP4HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL6047566 | 0.87 | HTR6 (0.56) | HTR6FABP4HTR1ADRD2HTR2A | |
| SCHEMBL4676473 | 0.85 | HTR6 (0.65) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL4309989 | 0.85 | HTR6 (0.65) | HTR6HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL28758136 | 0.84 | HTR6 (0.64) | HTR6HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL6047565 | 0.84 | HTR6 (0.64) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL4313475 | 0.82 | HTR6 (0.76) | HTR6FABP4HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | claimed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-7087750-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2006-08-08 | — | — | US | disclosed |
| US-20050256106-A1 | Novel compounds, their use and preparation | BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20020165251-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165251-A1 | Novel compounds, their use and preparation | HTR6, HTR1A, HTR5A | HTR6 1/4885FABP4 190/4885HTR1A 2/4885 |
| US-20050256106-A1 | Novel compounds, their use and preparation | HTR6, HTR3C, HTR1A | HTR6 1/4885FABP4 315/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.